ConductScience.org, home

Library / Trial comparisons

Aspirin vs Placebo Aspirin: Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.02030.01740.0237wilsonClinicalTrials.gov
Risk in group 20.02040.01750.0238wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.000129-0.00460.00434newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 20.9940.7991.24logClinicalTrials.gov
Odds ratio, group 1 over group 20.9940.7951.24logClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Aspirin than on Placebo Aspirin7,740from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1AspirinGroup includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm1577,740OG000ClinicalTrials.gov
Group 2Placebo AspirinGroup includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm1587,740OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypeSECONDARYClinicalTrials.gov
TitleNumber of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only)ClinicalTrials.gov
Description
Secondary efficacy assessments of aspirin involve intention-to-treat comparisons during the scheduled treatment period among all randomized participants on the first occurrence of:~Any incident gastrointestinal (GI) tract cancer (i.e. any GI cancer excluding pancreas and hepatobiliary), overall and after exclusion of the first three years of follow-up.
ClinicalTrials.gov
Time frameRandomized treatment phase during a mean of 7.4 yearsClinicalTrials.gov
PopulationParticipants taking aspirinClinicalTrials.gov

Trial 8

FieldValueSource
TitleASCEND: A Study of Cardiovascular Events iN DiabetesClinicalTrials.gov
NCT numberNCT00135226ClinicalTrials.gov
PhasesPHASE4ClinicalTrials.gov
ConditionsDiabetes MellitusClinicalTrials.gov
InterventionsAspirin, Omega-3 Ethyl Esters, Placebo Aspirin, Placebo Omega-3 Ethyl EstersClinicalTrials.gov
Lead sponsorUniversity of OxfordClinicalTrials.gov
Results first posted2019-04-26ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT00135226?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.